Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 3Recruiting 2Active not recruiting 2Withdrawn 1Suspended 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1

Conditions

Neoplasms 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1

Interventions

Specimen Handling 186pembrolizumab 151Magnetic Resonance Spectroscopy 151Carboplatin 114Biopsy 104Cyclophosphamide 96Cisplatin 88Paclitaxel 79Gemcitabine 71Bevacizumab 68fludarabine 60Nivolumab 58Fluorouracil 51Radiotherapy 49Dexamethasone 47Capecitabine 47Pemetrexed 46Oxaliplatin 44Docetaxel 44Rituximab 43Leucovorin 41Doxorubicin 40venetoclax 39durvalumab 39atezolizumab 39Temozolomide 32Standard of Care 32Radiation 32Cetuximab 32130-nm albumin-bound paclitaxel 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hyaluronoglucosaminidase × 30 days × Clear all
NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡